Create Free Account

By creating account you will get access to hot stocks & personalised emails

Johnson & Johnson

Healthcare US JNJ

144.66USD
-0.09(0.06%)

Last update at 2024-12-19T18:54:00Z

Day Range

143.60145.22
LowHigh

52 Week Range

143.80175.60
LowHigh

Fundamentals

  • Previous Close 144.75
  • Market Cap374235.79M
  • Volume3986962
  • P/E Ratio29.17
  • Dividend Yield3.06%
  • EBITDA35014.00M
  • Revenue TTM98656.00M
  • Revenue Per Share TTM38.16
  • Gross Profit TTM 63954.00M
  • Diluted EPS TTM5.33

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 21725.00M 22776.00M 16497.00M 17328.00M 17999.00M
Minority interest - - - - -
Net income 17941.00M 20878.00M 14714.00M 15119.00M 15297.00M
Selling general administrative 24765.00M 24659.00M 22084.00M 22178.00M 22540.00M
Selling and marketing expenses - - 22084.00M 22178.00M 22540.00M
Gross profit 63854.00M 63920.00M 54157.00M 54503.00M 54490.00M
Reconciled depreciation 6970.00M 7390.00M 7231.00M 7009.00M 6929.00M
Ebit 17054.00M 18309.00M 13111.00M 15117.00M 15623.00M
Ebitda 24024.00M 25699.00M 20342.00M 22126.00M 22552.00M
Depreciation and amortization 6970.00M 7390.00M 7231.00M 7009.00M 6929.00M
Non operating income net other -1381.00000M -436.00000M -2788.00000M -2168.00000M -794.00000M
Operating income 23917.00M 24417.00M 19824.00M 21009.00M 20781.00M
Other operating expenses 71240.00M 69228.00M 62670.00M 61089.00M 60406.00M
Interest expense 276.00M 183.00M 201.00M 318.00M 1005.00M
Tax provision 3784.00M 1898.00M 1783.00M 2209.00M 2702.00M
Interest income 490.00M 53.00M 111.00M 357.00M 611.00M
Net interest income 214.00M -130.00000M -90.00000M 39.00M -394.00000M
Extraordinary items - - 300.00M - -
Non recurring 1104.00M 1152.00M 428.00M 1156.00M 1377.00M
Other items - - - - -
Income tax expense 3784.00M 1898.00M 1783.00M 2209.00M 2702.00M
Total revenue 94943.00M 93775.00M 82584.00M 82059.00M 81581.00M
Total operating expenses 40151.00M 39373.00M 34243.00M 33533.00M 33315.00M
Cost of revenue 31089.00M 29855.00M 28427.00M 27556.00M 27091.00M
Total other income expense net -2192.00000M -1641.00000M -3327.00000M -3681.00000M -2782.00000M
Discontinued operations - - - - -
Net income from continuing ops 17941.00M 20878.00M 14714.00M 15119.00M 15297.00M
Net income applicable to common shares 17941.00M 20878.00M 14714.00M 15119.00M 15297.00M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 187378.00M 182018.00M 174894.00M 157728.00M 152954.00M
Intangible assets 48325.00M 46392.00M 53402.00M 47643.00M 47611.00M
Earning assets - - - - -
Other current assets 3132.00M 3701.00M 3132.00M 2486.00M 3649.00M
Total liab 110574.00M 107995.00M 111616.00M 98257.00M 93202.00M
Total stockholder equity 76804.00M 74023.00M 63278.00M 59471.00M 59752.00M
Deferred long term liab 6374.00M 7487.00M 7214.00M 5958.00M 7506.00M
Other current liab 31328.00M 30405.00M 30357.00M 26218.00M 13257.00M
Common stock 3120.00M 3120.00M 3120.00M 3120.00M 3120.00M
Capital stock 3120.00M 3120.00M 3120.00M 3120.00M 3120.00M
Retained earnings 128345.00M 123060.00M 113890.00M 110659.00M 106216.00M
Other liab 26584.00M 31784.00M 35388.00M 35083.00M 34285.00M
Good will 45231.00M 35246.00M 36393.00M 33639.00M 30453.00M
Other assets 17049.00M 17155.00M 3896.00M 11408.00M 11305.00M
Cash 14127.00M 14487.00M 13985.00M 17305.00M 18107.00M
Cash and equivalents 5368.00M 1901.00M 2102.00M 2864.00M 3397.00M
Total current liabilities 55802.00M 45226.00M 42493.00M 35964.00M 31230.00M
Current deferred revenue - - - 7819.00M 7640.00M
Net debt 25532.00M 19264.00M 21281.00M 10391.00M 12373.00M
Short term debt 12771.00M 3766.00M 2631.00M 1202.00M 2796.00M
Short long term debt 12771.00M 3766.00M 2631.00M 1202.00M 2796.00M
Short long term debt total 39659.00M 33751.00M 35266.00M 27696.00M 30480.00M
Other stockholder equity -41694.00000M -39099.00000M -38490.00000M -38417.00000M -34362.00000M
Property plant equipment 19803.00M 18962.00M 18766.00M 17658.00M 17035.00M
Total current assets 55294.00M 60979.00M 51237.00M 45274.00M 46033.00M
Long term investments - - - 1149.00M 517.00M
Net tangible assets -16752.00000M -13073.00000M -26517.00000M -21811.00000M -18312.00000M
Short term investments 9392.00M 17121.00M 11200.00M 1982.00M 1580.00M
Net receivables 16160.00M 15283.00M 13576.00M 14481.00M 14098.00M
Long term debt 26888.00M 29985.00M 32635.00M 26494.00M 27684.00M
Inventory 12483.00M 10387.00M 9344.00M 9020.00M 8599.00M
Accounts payable 11703.00M 11055.00M 9505.00M 8544.00M 7537.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -12967.00000M -13058.00000M -15242.00000M -15891.00000M -15222.00000M
Additional paid in capital - - - - -
Common stock total equity 3120.00M 3120.00M 3120.00M 3120.00M 3120.00M
Preferred stock total equity - - - - -
Retained earnings total equity 128345.00M 123060.00M 113890.00M 110659.00M 106216.00M
Treasury stock -41694.00000M -39099.00000M -38490.00000M -38417.00000M -34362.00000M
Accumulated amortization - - - - -
Non currrent assets other 9602.00M 10216.00M 6562.00M 5695.00M -7909.00000M
Deferred long term asset charges - - - 7819.00M 7640.00M
Non current assets total 132084.00M 121039.00M 123657.00M 112454.00M 106921.00M
Capital lease obligations - - - - -
Long term debt total 26888.00M 29985.00M 32635.00M 26494.00M 27684.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 9225.00M -5388.00000M -8952.00000M -533.00000M -1337.00000M
Change to liabilities -881.00000M 1376.00M 5885.00M 5485.00M 2107.00M
Total cashflows from investing activities -12371.00000M -8683.00000M -20825.00000M -6194.00000M -3167.00000M
Net borrowings 7452.00M -990.00000M 7095.00M -2881.00000M -3949.00000M
Total cash from financing activities -8871.00000M -14047.00000M -6120.00000M -18015.00000M -18510.00000M
Change to operating activities -1292.00000M -3025.00000M -2960.00000M 371.00M -2119.00000M
Net income 17941.00M 20878.00M 14714.00M 15119.00M 15297.00M
Change in cash -360.00000M 502.00M -3320.00000M -802.00000M 283.00M
Begin period cash flow 14487.00M 13985.00M 17305.00M 18107.00M 17824.00M
End period cash flow 14127.00M 14487.00M 13985.00M 17305.00M 18107.00M
Total cash from operating activities 21194.00M 23410.00M 23536.00M 23416.00M 22201.00M
Issuance of capital stock - - - - -
Depreciation 6970.00M 7390.00M 7231.00M 7009.00M 6929.00M
Other cashflows from investing activities -17587.00000M 357.00M -8526.00000M -2163.00000M 1840.00M
Dividends paid -11682.00000M -11032.00000M -10481.00000M -9917.00000M 9494.00M
Change to inventory -2527.00000M -1248.00000M -265.00000M -277.00000M -644.00000M
Change to account receivables -1290.00000M -2402.00000M 774.00M -289.00000M -1185.00000M
Sale purchase of stock -6035.00000M -3456.00000M -3221.00000M -6746.00000M -5868.00000M
Other cashflows from financing activities 17530.00M 395.00M -627.00000M 575.00M -148.00000M
Change to netincome 294.00M -620.00000M -1099.00000M -2577.00000M -28.00000M
Capital expenditures 4009.00M 3652.00M 3347.00M 3498.00M 3670.00M
Change receivables -1290.00000M -2402.00000M 774.00M -289.00000M -1185.00000M
Cash flows other operating 687.00M -1964.00000M -3704.00000M -1054.00000M -275.00000M
Exchange rate changes - - - - -241.00000M
Cash and cash equivalents changes -48.00000M 680.00M -3409.00000M -793.00000M 283.00M
Change in working capital -4011.00000M -4238.00000M 2690.00M 3865.00M 3.00M
Stock based compensation 1138.00M 1135.00M 1005.00M 977.00M 978.00M
Other non cash items 819.00M 324.00M -963.00000M -1078.00000M 10.00M
Free cash flow 17185.00M 19758.00M 20189.00M 19918.00M 18531.00M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - General

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
JNJ
Johnson & Johnson		 -0.09 0.06% 144.66 29.17 14.33 3.74 5.18 3.80 15.22
LLY
Eli Lilly and Company		 -5.84 0.76% 758.87 103.14 46.73 16.88 48.24 17.43 69.11
ABBV
AbbVie Inc		 0.02 0.01% 173.04 61.52 14.86 5.62 51.62 6.76 20.58
MRK
Merck & Company Inc		 1.11 1.13% 99.45 59.83 12.33 4.50 6.47 4.94 23.79
AZN
AstraZeneca PLC ADR		 0.03 0.04% 64.67 38.69 16.31 4.67 5.46 5.20 17.74

Reports Covered

Stock Research & News

View All

Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson

One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933

Key Executives

Name Title Year Born
Mr. Alex Gorsky Exec. Chairman 1960
Mr. Joaquin Duato CEO & Director 1963
Mr. Joseph J. Wolk CPA Exec. VP & CFO 1967
Ms. Jennifer L. Taubert Exec. VP & Worldwide Chairman of Pharmaceuticals 1964
Mr. Robert J. Decker Jr. Controller & Chief Accounting Officer 1972
Mr. James Swanson Exec. VP & Chief Information Officer NA
Ms. Jessica Moore VP of Investor Relations NA
Mr. Dirk Brinckman Chief Compliance Officer NA
Ms. Elizabeth Forminard Exec. VP & Gen. Counsel NA
Dr. Peter M. Fasolo Ph.D. Exec. VP & Chief HR Officer 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Our Company

Useful Links

Contact Us

ISO Certified Market Research

Kalkine Solutions Private Limited, authorized representative of Kalkine Pty Ltd, holds ISO 27001:2022 certification bearing Certificate No.- IC-IS-2404072

Our Company

Useful Links

Contact Us

Disclaimer

The information given by Kalkine Pty Ltd ABN34 154 808 312 (Australian Financial Services License Number 425376) on this website is general information or advice only.

It does not take into account any of your personal objectives, circumstances or needs. Choosing an investment is an important decision. If you do not feel confident making a decision based on the recommendations Kalkine has made in our reports, you should consider obtaining personal advice from an authorised adviser.

There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. Terms & Conditions have been provided for our services, please go through them and also read our Financial Services Guide.

Our website may contain information on past performance of particular investments. Past performance is not an indicator of future performance. Hypothetical returns may not reflect actual performance. Any displays of potential investment opportunities are for sample purposes only and may not actually be available to investors.

The information on the website does not constitute an offer to sell securities or a solicitation of an offer to buy securities. Our reports contain general recommendations to invest in securities.

Copyright 2024 Krish Capital Pty. Ltd. All rights reserved. No part of this website, or its content, may be reproduced in any form without our prior consent.